Trovagene Investor Relations Trovagene Investor Relations Trovagene Strengthens Board of Directors with Appointment of Oncology Development Veteran Dr. Athena Countouriotis Dr. Athena Countouriotis joins Trovagene's Board of Directors, bringing significant experience in oncology clinical development and orphan indications Wed, 20 Sep 2017 05:00:00 -0700 Trovagene Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017 Thu, 31 Aug 2017 05:00:00 -0700 Trovagene's PLK1 Inhibitor PCM-075 Demonstrates Synergy with a HDAC Inhibitor in Non-Hodgkin Lymphoma Cell Lines Additionally, Trovagene announces PCM-075 synergy in combination with more than ten chemo and targeted therapeutics across a broad range of solid tumor and hematologic malignancies Mon, 21 Aug 2017 05:00:00 -0700 Trovagene's PLK1 Inhibitor PCM-075, in Preclinical AML Data, Significantly Enhances the Efficacy of a FLT3 inhibitor in Combination Therapy Human AML xenograft with FLT3 mutation shows PCM-075 in combination with Quizartinib resulted in 96% tumor growth inhibition with tumor regression Wed, 16 Aug 2017 05:00:00 -0700 Trovagene Announces Second Quarter 2017 Company Highlights and Financial Results Wed, 09 Aug 2017 13:26:00 -0700